netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 1 to 9 of 9


Details
LDL Link Added : MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases : https://www.gov.uk/drug-safety-update/cdk4-slas
06/07/2023 11:10:13
(rpaylor )
LDL Link Added : NICE TA687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy : https://www.nice.org.uk/guidance/ta687
17/11/2022 14:31:44
(DavidS )
UPD sitematrix Changed from 0 to
17/11/2022 14:31:20
(DavidS )
UPD FurtherInformation Changed from
17/11/2022 14:31:20
(DavidS )
UPD Ribociclib (Kisqali®) NICE TA687
17/11/2022 14:31:20
(DavidS )
UPD Published from Draft Mode
09/05/2018 10:55:16
(LoweryM )
UPD Ribociclib (Kisqali®) updated
27/04/2018 11:47:15
(DavidS )
LDL Link Added : NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer : https://www.nice.org.uk/guidance/ta496
27/04/2018 11:46:34
(DavidS )
DUP Palbociclib (Kisqali®) NICE TA496 approved at APC (April 2018)
27/04/2018 11:46:11
(DavidS )

 

 
netFormulary